Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Carfilzomib + lenalidomide + dexamethasone versus lenalidomide + dexamethasone in relapsed multiple myeloma
NL-OMON38201Phase 3Active, not recruiting
- Sponsor
- Onyx Pharmaceuticals
- Start
- May 2011
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of carfilzomib, lenalidomide and dexamethasone in multiple myeloma (MM) (2 arms), sponsored by Onyx Pharmaceuticals. Primary endpoint: Progression-free survival. Started May 2011; status: active, not recruiting.
02
Drugs
carfilzomiblenalidomidedexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NL-OMON38201.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON38201.